|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BMERB1 |
Gene summary for BMERB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BMERB1 | Gene ID | 89927 |
| Gene name | bMERB domain containing 1 | |
| Gene Alias | C16orf45 | |
| Cytomap | 16p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96MC5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 89927 | BMERB1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 4.18e-01 | -0.0961 |
| 89927 | BMERB1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 8.94e-07 | 6.02e-01 | -0.0876 |
| 89927 | BMERB1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.01e-04 | 5.89e-01 | -0.0822 |
| 89927 | BMERB1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.35e-06 | 5.68e-01 | -0.0809 |
| 89927 | BMERB1 | HTA12-23-1 | Human | Pancreas | PDAC | 1.26e-03 | 5.45e-01 | 0.3405 |
| 89927 | BMERB1 | HTA12-25-1 | Human | Pancreas | PDAC | 4.35e-08 | 5.58e-01 | 0.313 |
| 89927 | BMERB1 | HTA12-26-1 | Human | Pancreas | PDAC | 8.35e-06 | 4.89e-01 | 0.3728 |
| 89927 | BMERB1 | HTA12-29-1 | Human | Pancreas | PDAC | 4.16e-29 | 6.73e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190290313 | Lung | AIS | regulation of supramolecular fiber organization | 66/1849 | 383/18723 | 5.01e-06 | 2.45e-04 | 66 |
| GO:001063913 | Lung | AIS | negative regulation of organelle organization | 61/1849 | 348/18723 | 6.53e-06 | 2.92e-04 | 61 |
| GO:005149412 | Lung | AIS | negative regulation of cytoskeleton organization | 33/1849 | 163/18723 | 4.95e-05 | 1.43e-03 | 33 |
| GO:190290413 | Lung | AIS | negative regulation of supramolecular fiber organization | 33/1849 | 167/18723 | 8.14e-05 | 2.03e-03 | 33 |
| GO:007050712 | Lung | AIS | regulation of microtubule cytoskeleton organization | 28/1849 | 148/18723 | 5.69e-04 | 8.89e-03 | 28 |
| GO:00400131 | Lung | AIS | negative regulation of locomotion | 57/1849 | 391/18723 | 1.80e-03 | 2.03e-02 | 57 |
| GO:003090011 | Lung | AIS | forebrain development | 55/1849 | 379/18723 | 2.37e-03 | 2.48e-02 | 55 |
| GO:00512711 | Lung | AIS | negative regulation of cellular component movement | 53/1849 | 367/18723 | 3.11e-03 | 3.00e-02 | 53 |
| GO:20001461 | Lung | AIS | negative regulation of cell motility | 52/1849 | 359/18723 | 3.18e-03 | 3.05e-02 | 52 |
| GO:00303361 | Lung | AIS | negative regulation of cell migration | 50/1849 | 344/18723 | 3.51e-03 | 3.33e-02 | 50 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |